Patents by Inventor Ho-Shen Lin

Ho-Shen Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7595403
    Abstract: A novel class of benzisothiazole-3(2H)-one compounds is disclosed together with the use of such compounds for inhibiting hepatic lipase and/or endothelial lipase activity for treatment, amelioration or prevention of hepatic lipase and/or endothelial lipase mediated diseases.
    Type: Grant
    Filed: March 25, 2004
    Date of Patent: September 29, 2009
    Assignee: Eli Lilly and Company
    Inventors: Patrick Irving Eacho, Patricia Sue Foxworthy-Mason, Ho-Shen Lin, Jose Eduardo Lopez, Marian Kazimierz Mosior, Michael Enrico Richett
  • Patent number: 7547691
    Abstract: The present invention provides compounds of Formula I: useful in the treatment of cancer and inflammatory diseases.
    Type: Grant
    Filed: November 15, 2006
    Date of Patent: June 16, 2009
    Assignee: Eli Lilly and Company
    Inventors: Karl Robert Dahnke, Ho-Shen Lin, Michael Enrico Richett, Chuan Shih, Q May Wang, Bo Zhang
  • Publication number: 20080306082
    Abstract: The present invention provides compounds of Formula I: useful in the treatment of cancer and inflammatory diseases.
    Type: Application
    Filed: November 15, 2006
    Publication date: December 11, 2008
    Inventors: Karl Robert Dahnke, Ho-Shen Lin, Michael Enrico Richett, Chuan Shih, Q May Wang, Bo Zhang
  • Patent number: 7449477
    Abstract: The present invention relates to compounds Formula (I) as inhibitors of AKT activity, which are useful for the treatment of susceptible neoplasms and viral infections.
    Type: Grant
    Filed: November 22, 2004
    Date of Patent: November 11, 2008
    Assignee: Eli Lilly and Company
    Inventors: David Anthony Barda, Kenneth James Henry, Jr., Jianping Huang, Sajan Joseph, Ho-Shen Lin, Michael Enrico Richett
  • Patent number: 7414063
    Abstract: The present invention relates to compounds Formula (I): as inhibitors of AKT activity, which are useful for the treatment of susceptible neoplasms and viral infections.
    Type: Grant
    Filed: March 25, 2004
    Date of Patent: August 19, 2008
    Assignee: Eli Lilly and Company
    Inventors: Rima Salim Al-Awar, David Anthony Barda, Albert Gerard Dee, Kenneth James Henry, Jr., Sajan Joseph, Ho-Shen Lin, Jose Eduardo Lopez, Michael Enrico Richett, Carmen Somoza
  • Patent number: 7250430
    Abstract: The present invention provides antineoplastic compounds of the formula: and antineoplastic methods.
    Type: Grant
    Filed: June 6, 2006
    Date of Patent: July 31, 2007
    Assignee: Eli Lilly and Company
    Inventors: Cora Sue Grossman, Philip Arthur Hipskind, Ho-Shen Lin, Karen Lynn Lobb, Beatriz Lopez de Uralde Garmendia, Jose Eduardo Lopez, Mary Margaret Mader, Michael Enrico Richett, Chuan Shih, Alfonso De Dios
  • Patent number: 7217727
    Abstract: A novel class of 3-oxo-3H-benzo[d]isoxazole carboxamide compounds is disclosed together with the use of such compounds for inhibiting hepatic lipase and/or endothelial lipase activity for treatment, amelioration or prevention of hepatic lipase and/or endothelial lipase mediated diseases.
    Type: Grant
    Filed: March 25, 2004
    Date of Patent: May 15, 2007
    Assignee: Eli Lilly and Company
    Inventors: Patrick Irving Eacho, Patricia Sue Foxworthy-Mason, Ho-Shen Lin, Jose Eduardo Lopez, Marian Kazimierz Mosior, Michael Enrico Richett
  • Patent number: 7183320
    Abstract: The present invention provides antitumor compounds of the formula (I), and antitumor methods
    Type: Grant
    Filed: May 24, 2002
    Date of Patent: February 27, 2007
    Assignee: Eli Lilly and Company
    Inventors: Chuan Shih, Cora Sue Grossman, Karen Lynn Lobb, Thomas Hughes Corbett, Ho-Shen Lin, Philip Arthur Hipskind
  • Publication number: 20070043040
    Abstract: The present invention relates to compounds Formula (I): as inhibitors of AKT activity, which are useful for the treatment of susceptible neoplasms and viral infections.
    Type: Application
    Filed: March 25, 2004
    Publication date: February 22, 2007
    Inventors: Rima Al-Awar, David Barda, Albert Dee, Kenneth Henry Jr, Sajan Joseph, Ho-Shen Lin, Jose Lopez, Michael Richett, Carmen Somoza
  • Publication number: 20070037796
    Abstract: The present invention relates to compounds Formula (I) as inhibitors of AKT activity, which are useful for the treatment of susceptible neoplasms and viral infections.
    Type: Application
    Filed: November 22, 2004
    Publication date: February 15, 2007
    Inventors: David Barda, Kenneth Henry, Jianping Huang, Sajan Joseph, Ho-Shen Lin, Michael Richett
  • Publication number: 20060276522
    Abstract: A novel class of benzisothiazole-3(2H)-one compounds is disclosed together with the use of such compounds for inhibiting hepatic lipase and/or endothelial lipase activity for treatment, amelioration or prevention of hepatic lipase and/or endothelial lipase mediated diseases.
    Type: Application
    Filed: March 25, 2004
    Publication date: December 7, 2006
    Applicant: Eli Lilly And Company
    Inventors: Patrick Eacho, Patricia Foxworthy-Mason, Ho-Shen Lin, Jose Lopez, Marian Moslor, Michael Richett
  • Publication number: 20060223871
    Abstract: The present invention provides antineoplastic compounds of the formula: and antineoplastic methods.
    Type: Application
    Filed: June 6, 2006
    Publication date: October 5, 2006
    Inventors: Cora Grossman, Philip Hipskind, Ho-Shen Lin, Karen Lobb, Beatriz Lopez de Uralde Garmendia, Jose Lopez, Mary Mader, Michael Richett, Chuan Shih, Alfonso De Dios
  • Publication number: 20060211755
    Abstract: The present invention provides a compound of formula I (1) wherein; R, is selected from the group consisting of C5-C13alkyl; C,—C,2haloalkyl, C4C,2alkenyl, C4-C12alkynyl, or C,—C5alkylcycloalkyl, C3-C8cycloalkyl, C, C5alkylheterocyclic, and aryl, wherein the, cycloalkyl, cycloalkenyl, heterocyclic and aryl substituents are optionally substituted with one to three substituents independently selected from C,—C8a)kyl, C,—C8haloalkyl, ?C2-CBalkenyl, C2-C8a)kynyl, phenyl, benzyl, hydroxy, C,—C5 alkoxy, (C}12)m000C,—Csalkyl, (CH2)mNRaRb, and C,C4alkylcycloalkyl; wherein W and Rb are independently selected from hydrogen, C,CBalkyl, C2-CBalkenyl, C2-CBalkynyl, and C,—C5alkylcycloalkyl; R2 is hydrogen; R3, R4, R5, and R6, are independently selected from hydrogen, C,—C12alkyl, C2C,2haloalkyl, C2-C,2 alkenyl, C2-C12alkynyl, C,—C12alkylaryl, C,—C12alkylcyclohexyl, C, C12alkylcyclopentyl, C,—C12alkylheterocyclic, (CH2)m000H, (CH2)mC0(C,—C,o)alkyl, (CH2)m COO(C,—C,o)alkyl, (CH2)mCOO(C1-C,o)alkylaryl, C,—C,oalkylamino, halo
    Type: Application
    Filed: March 25, 2004
    Publication date: September 21, 2006
    Applicant: Eli Lilly and Company Patent Division
    Inventors: Patrick Eacho, Patricia Foxworthy-Mason, Ho-Shen Lin, Jose Lopez, Marian Mosior, Michael Richett
  • Patent number: 7084170
    Abstract: The present invention provides antineoplastic compounds of the formula: and antineoplastic methods.
    Type: Grant
    Filed: October 15, 2002
    Date of Patent: August 1, 2006
    Assignee: Eli Lilly and Company
    Inventors: Cora Sue Grossman, Philip Arthur Hipskind, Ho-Shen Lin, Karen Lynn Lobb, Beatriz Lopez de Uralde Garmendia, Jose Eduardo Lopez, Mary Margaret Mader, Michael Enrico Richett, Chuan Shih, Alfonso De Dios
  • Publication number: 20060116409
    Abstract: A novel class of 3-oxo-3H-benzo[d]isoxazole carboxamide compounds is disclosed together with the use of such compounds for inhibiting hepatic lipase and/or endothelial lipase activity for treatment, amelioration or prevention of hepatic lipase and/or endothelial lipase mediated diseases.
    Type: Application
    Filed: March 25, 2004
    Publication date: June 1, 2006
    Inventors: Patrick Eacho, Patricia Foxworthy-Mason, Ho-Shen Lin, Jose Lopez, Marian Mosior, Michael Richett
  • Patent number: 6992100
    Abstract: A novel class of tetracyclic compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: January 31, 2006
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Jr., Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, John David Jandzinski
  • Patent number: 6974831
    Abstract: A novel class of cycloalkyl fused indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: December 13, 2005
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith
  • Patent number: 6939890
    Abstract: A class of novel indole is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: July 30, 2003
    Date of Patent: September 6, 2005
    Assignee: Eli Lilly and Company
    Inventors: Richard Waltz Harper, Ho-Shen Lin, Michael Enrico Richett
  • Patent number: 6933313
    Abstract: Carbazoles of formula (I) with R2=hydroxyfunctional amide (hydroxamic or esters) are disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock.
    Type: Grant
    Filed: March 15, 2002
    Date of Patent: August 23, 2005
    Assignee: Eli Lilly and Company
    Inventors: Richard Waltz Harper, Ho-Shen Lin, Michael Enrico Richett
  • Patent number: 6930123
    Abstract: A novel class of benz[f]indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: August 16, 2005
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith